Beam Therapeutics Inc (BEAM) - News Archive

Beam Therapeutics, a prominent player in the gene-editing sector, has released promising new data on its investigational therapy, BEAM-302, for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) at the 7th Global Re...

Beam Therapeutics Inc. has made significant strides in the treatment of sickle cell disease, presenting groundbreaking new data from its BEACON Phase 1/2 clinical trial of BEAM-101 during the recent American Society of...

Advancements in Hematology: Beam Therapeutics Innovative Research Amidst Financial Challenges Beam Therapeutics, a leading biotechnology company focused on developing precision genetic medicines through base editing, re...

Beam Therapeutics Groundbreaking BEAM-302 Enters Clinical Trial for Alpha-1 Antitrypsin Deficiency, While Suppliers Face Financial ChallengesConclusion:Beam Therapeutics Inc. s dosing of the first patient with BEAM-302...

Beam Therapeutics, a leading biotechnology company specializing in precision genetic medicines through base editing, has announced significant progress in the manufacturing process for BEAM-101, an investigational base...

Beam Therapeutics Triumphs in Manufacturing, Faces Financial Turbulence: A Close Look Ahead of the 2024 EHA Hybrid Congress In the ever-evolving realm of biotechnology, Beam Therapeutics Inc., a trailblazer in the field...

Beam Therapeutics Announces Clearance of Clinical Trial Authorization Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)Beam Therapeutics, a leading biotechnology company, has recently a...